15 studies found for:    HYPOGONADOTROPIC HYPOGONADISM 1 WITH OR WITHOUT ANOSMIA
Show Display Options
Rank Status Study
1 Terminated
Has Results
Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])
Condition: Hypogonadotropic Hypogonadism
Interventions: Drug: Luveris® 75 IU;   Drug: Luveris® 25 IU;   Drug: Placebo;   Drug: Recombinant human follicle stimulating hormone (r-hFSH);   Drug: Recombinant human chorionic gonadotropin (r-hCG)
2 Completed Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions
Conditions: Primary Hypogonadism;   Hypogonadotropic Hypogonadism
Interventions: Drug: Testosterone Topical Gel, 1.62% Metered Pump;   Drug: AndroGel (testosterone gel) 1.62% Metered-Dose Pump
3 Completed Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP
Condition: Hypogonadotropic Hypogonadism
Interventions: Drug: Pergoveris: 150IU r-hFSH + 75IU r-hLH;   Drug: Menopur: HMG-HP (150 IU)
4 Completed Pharmacokinetic Evaluation of Testosterone Gel (1%)
Conditions: Primary or Secondary Hypogonadism;   Constitutional Delay in Growth and Puberty (CDGP)
Intervention: Drug: Testosterone Gel (1%)
5 Completed Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism
Conditions: Primary or Secondary Hypogonadism;   Constitutional Delay in Growth and Puberty (CDGP)
Intervention: Drug: Testosterone Gel (1%)
6 Active, not recruiting A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Condition: Secondary Hypogonadism
Interventions: Drug: Androxal 12.5 mg or 25 mg;   Drug: AndroGel 1.62%;   Drug: Placebo Capsules;   Drug: Placebo Gel
7 Active, not recruiting A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Condition: Secondary Hypogonadism
Interventions: Drug: Androxal 12.5 mg/25 mg;   Drug: Placebo Capsules;   Drug: AndroGel 1.62%;   Drug: Placebo Gel
8 Recruiting Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders
Conditions: Hypogonadism;   Kallmann Syndrome;   Puberty, Delayed;   Puberty, Precocious;   Hypothalamic Amenorrhea;   Anosmia;   GnRH Deficiency
Intervention:
9 Completed Experiments to Test How and Why the Sense of Smell Differs Between People
Condition: Specific Anosmias
Intervention: Behavioral: smell tests
10 Not yet recruiting Does Cardiopulmonary Bypass Change Olfaction?
Condition: Anosmia.
Intervention:
11 Completed Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism
Condition: Hypogonadism
Intervention: Drug: Sustanon
12 Active, not recruiting Hormonal Causes of Menstrual-Related Mood Disorders
Conditions: Mood Disorders;   Depression
Intervention:
13 Recruiting Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery
Conditions: Olfaction Disorders;   Sinusitis;   Paranasal Sinus Diseases
Intervention: Drug: Budesonide Respules
14 Recruiting The Genetic Investigation of Reproductive Disorders (Including Kallmann Syndrome)
Conditions: Kallmann Syndrome;   Hypogonadotropic Hypogonadism;   Hypothalamic Amenorrhea;   Polycystic Ovarian Syndrome;   Precocious Puberty
Intervention:
15 Unknown  Is Pentoxifylline Able to Improve Olfactory Sensitivity?
Condition: Olfaction Disorders
Intervention: Drug: Pentoxifylline retard 400mg

Indicates status has not been verified in more than two years